Literature DB >> 10755616

Sequential involvement of NFAT and Egr transcription factors in FasL regulation.

J Rengarajan1, P R Mittelstadt, H W Mages, A J Gerth, R A Kroczek, J D Ashwell, L H Glimcher.   

Abstract

The critical function of NFAT proteins in maintaining lymphoid homeostasis was revealed in mice lacking both NFATp and NFAT4 (DKO). DKO mice exhibit increased lymphoproliferation, decreased activation-induced cell death, and impaired induction of FasL. The transcription factors Egr2 and Egr3 are potent activators of FasL expression. Here we find that Egr2 and Egr3 are NFAT target genes. Activation of FasL occurs via the NFAT-dependent induction of Egr3, as demonstrated by the ability of exogenously provided NFATp to restore Egr-dependent FasL promoter activity in DKO lymph node cells. Further, Egr3 expression is enriched in Th1 cells, suggesting a molecular basis for the known preferential expression of FasL in the Th1 versus Th2 subset.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755616     DOI: 10.1016/s1074-7613(00)80182-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  73 in total

Review 1.  T cell apoptosis and reactive oxygen species.

Authors:  David A Hildeman; Thomas Mitchell; John Kappler; Philippa Marrack
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

2.  EGR2 is critical for peripheral naïve T-cell differentiation and the T-cell response to influenza.

Authors:  Ning Du; Hyokjoon Kwon; Peng Li; Erin E West; Jangsuk Oh; Wei Liao; Zuxi Yu; Min Ren; Warren J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

3.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 4.  Tenuous paths in unexplored territory: From T cell receptor signaling to effector gene expression during thymocyte selection.

Authors:  Lie Wang; Yumei Xiong; Rémy Bosselut
Journal:  Semin Immunol       Date:  2010-10       Impact factor: 11.130

5.  The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Authors:  Feng Fang; Kohtaro Ooka; Swati Bhattacharyya; Swati Bhattachyya; Jun Wei; Minghua Wu; Pan Du; Simon Lin; Francesco Del Galdo; Carol A Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

6.  Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation.

Authors:  Maximilian Diehn; Ash A Alizadeh; Oliver J Rando; Chih Long Liu; Kryn Stankunas; David Botstein; Gerald R Crabtree; Patrick O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

7.  NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes.

Authors:  Leonardo K Teixeira; Nina Carrossini; Cristiane Sécca; José E Kroll; Déborah C DaCunha; Douglas V Faget; Lilian D S Carvalho; Sandro J de Souza; João P B Viola
Journal:  Cell Cycle       Date:  2016-07-11       Impact factor: 4.534

8.  Early growth response-1 is required for CD154 transcription.

Authors:  Randy Q Cron; Rupa Bandyopadhyay; Anna Genin; Michael Brunner; Gilbert J Kersh; Jiyi Yin; Terri H Finkel; Mary K Crow
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

9.  Small GTPase RhoE/Rnd3 is a critical regulator of Notch1 signaling.

Authors:  Zehua Zhu; Kristina Todorova; Kevin K Lee; Jun Wang; Eunjeong Kwon; Ivan Kehayov; Hyung-Gu Kim; Vihren Kolev; G Paolo Dotto; Sam W Lee; Anna Mandinova
Journal:  Cancer Res       Date:  2014-02-13       Impact factor: 12.701

10.  Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination.

Authors:  Vivian T Thieu; Qing Yu; Hua-Chen Chang; Norman Yeh; Evelyn T Nguyen; Sarita Sehra; Mark H Kaplan
Journal:  Immunity       Date:  2008-11-14       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.